Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcit... (Source: BMC Medicine)
Source: BMC Medicine - March 7, 2024 Category: Internal Medicine Authors: Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu and Yan Xie Tags: Research article Source Type: research
Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma
In conclusion, the present study provides novel insights into the role of ICD in DLBCL by identifying a new biomarker for the disease and may have implications for the development of immune-targeted therapies for the tumor.PMID:38446321 | DOI:10.1007/s10528-024-10697-6 (Source: Biochemical Genetics)
Source: Biochemical Genetics - March 6, 2024 Category: Genetics & Stem Cells Authors: Shengqiang Huang Wenbin Liu Qiuling Zhao Ting Chen Ruyi Huang Liangliang Dong Zilin Nian Lin Yang Source Type: research
Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma
In conclusion, the present study provides novel insights into the role of ICD in DLBCL by identifying a new biomarker for the disease and may have implications for the development of immune-targeted therapies for the tumor.PMID:38446321 | DOI:10.1007/s10528-024-10697-6 (Source: Biochemical Genetics)
Source: Biochemical Genetics - March 6, 2024 Category: Genetics & Stem Cells Authors: Shengqiang Huang Wenbin Liu Qiuling Zhao Ting Chen Ruyi Huang Liangliang Dong Zilin Nian Lin Yang Source Type: research
Combined exercise on fatigue, quality of life and physical functioning in people under chemotherapy with oxaliplatin: Systematic review and meta-analysis
To investigate the effects of combined exercise on fatigue, anxiety, depression, quality of life and physical functioning in gastroinstestinal neoplasm in people under chemotherapy with oxaliplatin treatment. (Source: Journal of Bodywork and Movement Therapies)
Source: Journal of Bodywork and Movement Therapies - March 6, 2024 Category: Physiotherapy Authors: Micheli Bernardone Saquetto, Roberto Mathias Machado, Isabelle Bomfim, Clarissa Mathias, Marcela Rodrigues de Castro, Mansueto Gomes Neto Source Type: research
Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study
CONCLUSIONS: Third-line chemotherapy re-use was effective in mCRC. Those with more aggressive characteristics (RAS/RAF mutant, larger tumor burden) or better efficacy of previous chemotherapy (longer PFS) were more appropriate for third-line chemotherapy, rather than anti-angiogenic monotherapy.PMID:38443891 | DOI:10.1186/s12885-024-12072-5 (Source: Cancer Control)
Source: Cancer Control - March 5, 2024 Category: Cancer & Oncology Authors: Jingjing Duan Lila Zhu Yinghui Shi Weixue Wang Tongtong Wang Tao Ning Le Zhang Ming Bai Hongli Li Rui Liu Shaohua Ge Xia Wang Yuchong Yang Zhi Ji Feixue Wang Yansha Sun Yi Ba Ting Deng Source Type: research
Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction
Glioma is easy to develop resistance to temozolomide (TMZ). TMZ-resistant glioma secretes interleukin-10 (IL-10) and transforming growth factor- β (TGF-β), recruiting regulatory T cell (Treg) and inhibiting the ac... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - March 5, 2024 Category: Nanotechnology Authors: Xue Li, Ying Cheng, Zhifu Yang, Qifeng Ji, Menglei Huan, Weiliang Ye, Miao Liu, Bangle Zhang, Daozhou Liu and Siyuan Zhou Tags: Research Source Type: research
Nanoparticles integrated with mild photothermal therapy and oxaliplatin for tumor chemotherapy and immunotherapy
Nanomedicine, Ahead of Print. (Source: Future Medicine: Nanomedicine)
Source: Future Medicine: Nanomedicine - March 4, 2024 Category: Nanotechnology Authors: Qiong Yi Shumin He Kai Liao Zongxiang Yue Ling Mei Source Type: research
Nanoparticles integrated with mild photothermal therapy and oxaliplatin for tumor chemotherapy and immunotherapy
Nanomedicine, Ahead of Print. (Source: Nanomedicine)
Source: Nanomedicine - March 4, 2024 Category: Nanotechnology Authors: Qiong Yi Shumin He Kai Liao Zongxiang Yue Ling Mei Source Type: research
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
CONCLUSION: Elderly U.S. Medicare beneficiaries diagnosed with DLBCL who initiated R-GemOx treatment in the R/R setting have poor overall survival, high rates of HCRU, and substantial costs.PMID:38433043 | DOI:10.1016/j.clml.2024.01.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 3, 2024 Category: Cancer & Oncology Authors: Mahek Garg Justin Puckett Sachin Kamal-Bahl Monika Raut Katherine Elizabeth Ryland Jalpa A Doshi Scott F Huntington Source Type: research
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
CONCLUSION: Elderly U.S. Medicare beneficiaries diagnosed with DLBCL who initiated R-GemOx treatment in the R/R setting have poor overall survival, high rates of HCRU, and substantial costs.PMID:38433043 | DOI:10.1016/j.clml.2024.01.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 3, 2024 Category: Cancer & Oncology Authors: Mahek Garg Justin Puckett Sachin Kamal-Bahl Monika Raut Katherine Elizabeth Ryland Jalpa A Doshi Scott F Huntington Source Type: research
High-dose oxaliplatin induces severe hypersensitivity reactions and high recurrence rates during rechallenge in patients treated with hepatic arterial infusion chemotherapy
CONCLUSIONS: The administration of OXA doses is a risk factor for OXA-induced severe hypersensitivity reactions in patients treated with HAIC (OXA). Rechallenging HAIC with OXA appears to be associated with a higher recurrence rate of the HSR.PMID:38430809 | DOI:10.1016/j.intimp.2024.111767 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 2, 2024 Category: Allergy & Immunology Authors: Baojiang Liu Song Gao Jianhai Guo Fuxin Kou Shaoxing Liu Xin Zhang Aiwei Feng Xiaodong Wang Guang Cao Liang Xu Hui Chen Peng Liu Haifeng Xu Qinzong Gao Renjie Yang Xu Zhu Source Type: research
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minut...
Source: Atherosclerosis - March 1, 2024 Category: Cardiology Authors: Manon Gouez Am élie Rébillard Amandine Thomas Sabine Beaumel Eva-Laure Matera Etienne Gouraud Luz Orfila Brice Martin Olivia P érol C édric Chaveroux Erica N Chirico Charles Dumontet B éatrice Fervers Vincent Pialoux Source Type: research
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
CONCLUSIONS: This study did not meet the primary endpoint. Hence, FOLFIRI plus AFL should not be used after FTD/TPI plus BEV for metastatic colorectal cancer. Further studies are needed to determine factors not targeted by AFL that may affect the efficacy of the treatment.CLINICAL TRIAL REGISTRATION: jRCTs041190100.PMID:38427280 | DOI:10.1007/s11523-024-01043-2 (Source: Cancer Control)
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Toshihiko Matsumoto Yoshiyuki Yamamoto Masahito Kotaka Toshiki Masuishi Yasushi Tsuji Hirokazu Shoji Kenro Hirata Takao Tsuduki Akitaka Makiyama Naoki Izawa Naoki Takahashi Masahiro Tsuda Hisateru Yasui Takashi Ohta Yosuke Kito Satoshi Otsu Shuichi Hirona Source Type: research
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minut...
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Manon Gouez Am élie Rébillard Amandine Thomas Sabine Beaumel Eva-Laure Matera Etienne Gouraud Luz Orfila Brice Martin Olivia P érol C édric Chaveroux Erica N Chirico Charles Dumontet B éatrice Fervers Vincent Pialoux Source Type: research
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice
In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE). Both TRT and TRT-EXE received ICI: anti-PD1-1 (1 injection/week) and capecitabine + oxaliplatin (5 times a week) for 1 week (experimentation 1), 3 weeks (experimentation 2). TRT-EXE and EXE groups were submitted to 50 minut...
Source: Atherosclerosis - March 1, 2024 Category: Cardiology Authors: Manon Gouez Am élie Rébillard Amandine Thomas Sabine Beaumel Eva-Laure Matera Etienne Gouraud Luz Orfila Brice Martin Olivia P érol C édric Chaveroux Erica N Chirico Charles Dumontet B éatrice Fervers Vincent Pialoux Source Type: research
